

UPDATED COMPANY PRESENTATION

Adelaide, Australia, 23 June 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**), is pleased to share an updated Company Presentation. The presentation will be uploaded to the Company website.

The Company's presentation is attached.

Approved for release by the Company's Chair of the Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com

ASX: CC5

AI-powered microbiology

*Revolutionising microbial quality control
in pharmaceutical manufacturing*

Brent Barnes, CEO and Managing Director
June 2026



Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States.

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.




Sterile drugs



Problem

Millions of culture plates are manually read and reported annually during pharmaceutical manufacturing



Incorrect results costly

High cost of failure

Up to US\$1bn lost revenue¹

Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastrophic impact is patient death

Regulatory scrutiny

116% regulatory increase²

Rise in regulatory observations to drug establishments creates compliance challenges

Inefficient

Up to 98% zero growth plates³

Millions of plates reviewed annually, majority of plates have no growth yet require dual analyst verification, wasting resources



Environmental monitoring today

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates



Environmental monitoring



Cleanrooms

(pharmaceutical manufacturing)



Incubation (3-7 days)



Critical decision point

Culture plate reading, reporting. Result to release pharmaceutical product



No Growth
→ Batch release




Growth detected
→ Batch held
→ Investigation



Solution

Digital disruption

APAS INDEPENDENCE



Solution: APAS

Automated Plate Assessment System



Cutting edge AI technology

Machine learning for microbiology applications



Demonstrated performance

Extensive scientific data, faster than microbiologist



Improved data integrity

Automatic data trails and audit reports



Easy integration and user operation

Simple plug and play technology



Clever Culture Systems.

ASX: CC5

6

Environmental monitoring with APAS

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates



Environmental monitoring



Cleanrooms

(pharmaceutical manufacturing)



Incubation
(3-7 days)

Critical decision point

Automated culture plate reading



APAS INDEPENDENCE



No Growth >90%
→ Batch release
automatically



Growth detected
~2-10% reviewed
manually



Up to \$1.2M revenue per APAS Independence sale⁴

Includes up-front Capex and Annual Recurring Revenue (ARR) streams



Product / Service	Description	Revenue Model	Approx. Split
APAS [®] Independence	Laboratory Instrumentation	Upfront Capex (inc. financing options)	40%
APAS Apps [®]	AI Software Licence	 ARR	40%
APAS Service ²	Support and maintenance services	 ARR	15%
Implementation Services	Instrument connectivity, technical data and validation support	One-off	5%

Opportunity

Total addressable pharmaceutical market – \$2.8B⁴

Market Opportunity – sterile pharmaceutical manufacturing

Market CAGR growth >8%⁵



Annual SaaS Opportunity

\$230M ARR⁶

\$1.6B⁴

SaaS / ARR

Annual AI software license + hardware
maintenance over 7 years



\$1.2B⁴

Up-front CAPEX

Instrument hardware

Every instrument sale worth up to \$1.2M⁴ over 7 years

Commercial progress against TAM

Current sales ✓

22

Instruments

10

customers

~\$1.3M⁷ ARR

Qualified Opportunity: 180 instruments

Expand with current
customers

100⁸

Instruments



Qualified pipeline (active
engagement)

80⁹

Instruments

\$216M total value

\$19M ARR

TAM Penetration

~9%¹⁰

of TAM are already customers
and part of qualified pipeline



Land & Expand with global pharmaceutical customers

How it works



Current global pharmaceutical customers

AstraZeneca 12 instruments – global sites	Pfizer Global pharma customer
Bristol Myers Squibb Global pharma customer	Novo Nordisk Global pharma customer
Boehringer Ingelheim Global pharma customer	CSL Behring Global pharma customer
Thermo Fisher (Patheon) Global pharma CDMO customer	Global pharma customer <i>Confidential</i>

Expand opportunity – global pharma customers

~100 APAS instruments	~\$51M CAPEX Opportunity	~\$10M ARR SaaS / Recurring
---------------------------------	------------------------------------	---------------------------------------

Competition

Different automation approach

Incubation and reading technologies

- Requires continuous reading between incubator and imaging platform
- Incubation size restricts volume capacity (60-132 plates per day capacity)

3P System – bioMérieux (Interscience OEM)

Incubator capacity **300** plates
~60 plates per day¹



Growth Direct – Rapid Micro Biosystems (NASDAQ::RPID)

Incubator capacity **~660** plates
~132 plates per day (5-day incubation time)



APAS Independence: end point reader

APAS delivers scale

- 1 APAS instrument automates 1,600 plates per day
- Customers use their existing low-cost, high-volume incubators



Global installed base of APAS® Independence instruments

Asia-Pac: 7 instruments

USA: 11 instruments

Europe: 19 instruments

- 22 instruments for Pharmaceutical market (*units sold + under evaluation + committed order*)
- 15 instruments for Clinical market

- APAS sales
- APAS Service and training Hub
- Sales Team

Experienced

Board and Management

Focused on expansion into pharmaceutical manufacturing industry

- Board and Management shareholding 20%+
- International experience with healthcare, technology and pharmaceutical manufacturing expertise
- Extensive public listed ASX experience in micro-cap and high-growth companies



Brent Barnes
CEO and MD, AU
Aug-16 start



Rebecca Wilson
Chair, AU
Jul-23 start



Dan Hill
NED, AU
Dec-23 start



Ian Wisenberg
NED, US
Oct-24 start



Ray Ridge
CFO and
CoSec, AU



APAS INDEPENDENCE



Strong product-market fit evidenced by 8 leading global pharmaceutical companies

Land-and-expand commercialisation strategy

Capital efficient growth model driven by existing customers + qualified pipeline

Potential revenue \$216M + \$19M ARR

High margin SaaS model

Growing installed base underpins financial outlook

Step-change sales increase anticipated in FY27

Expected to deliver financial growth



References:

¹ www.researchandmarkets.com, Global Pharmaceuticals Market Report 2021: Covid-19 Impact and Recovery to 2030.

² <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations>

³ <https://www.cleverculturesystems.com/scientific-library/apas-pharmagc-ai-culture-plate-reading>

⁴ Australian dollars (USD:AUD: 1.4). Market opportunity of AU\$2.8B based on 2,300 APAS® Independence over expected 7 years based on internal Company market research

⁵ Compound Annual Growth Rate of 8.1% from 2026 to 2033 (<https://www.coherentmarketinsights.com/market-insight/sterile-injectables-market-201>)

⁶ AUD\$100,000 ARR per APAS® Independence sold multiplied by TAM of 2,300 APAS® Independence instruments = AUD\$230M

⁷ AUD\$1.3M ARR expectations based on current installed base due to product sales mix. Lower ARR for Clinical market sales and lower ARR for the 12 AstraZeneca pharmaceutical market instrument sales to compensate for the >AUD\$1M pre-payment for R&D services (https://cdn.prod.website-files.com/6615dec696e9446eaf6b7c32/671f16ceaf350741abc9e900_9-January-2023-AstraZeneca-Partners-LBT-for-APAS%C2%AE-Pharma-Development.pdf)

⁸ The 100 APAS® Independence instrument potential is a Company estimate of the opportunity with existing global pharmaceutical customers: AstraZeneca, Novo Nordisk, Bristol Myers Squibb, Pfizer, Thermo Fisher (Patheon), Boehringer Ingelheim, CSL, un-named Top-20

⁹ The 80 APAS® Independence instrument potential is a Company estimate of the opportunity from the current customer qualified pipeline

¹⁰ The TAM penetration calculation is 22 + 180 APAS® Independence instruments divided by the TAM of 2,300

